ARL4C also plays a role in drug targeting; miR-26 promotes foam cell formation by reducing ABCA1 and ARL4C expression, supporting the development of drugs targeting atherosclerosis (Chen et al., 2024). This evidence concerns the gene ABCA1 and atherosclerosis.